Skip to main content
Clinical Trials/NL-OMON47928
NL-OMON47928
Recruiting
Phase 2

A prospective, randomized pilot study of the immunomodulatory effects of azithromycin in adults with pulmonary tuberculosis - AZT_DSTB_BB

niversitair Medisch Centrum Groningen0 sites24 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
niversitair Medisch Centrum Groningen
Enrollment
24
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • \- Microbiological proven diagnosis of drug sensitive pulmonary tuberculosis (by culture and/or molecular test.; absence of resistance genes such as rpob, inha, katg)
  • \- Written informed consent

Exclusion Criteria

  • \- Patient reported previous history of treatment for tuberculosis
  • \- Patients younger than 18 years
  • \- Pregnancy or breast feeding
  • \- Patients with hypersensitivity to macrolide antibiotics
  • \- Treatment with any macrolide in the previous month
  • \- Treatment with any tetracycline in the previous month
  • \- Treatment with any inhaled or oral corticosteroid in the previous month
  • \- Concomitant treatment with analgesic (NSAIDs)/immunosuppressant drugs (except paracetamol). See attachment A for a full list of these drugs.
  • \- Treatment with digoxin
  • \- Patients with gastrointestinal complaints, like diarrhea and vomiting (\>\=grade 2, observed; diarrhea: increase of 4\-6 stools per day over baseline; vomiting: \>\=3\-5 episodes (separated by 5 minutes) in 24 hours)

Outcomes

Primary Outcomes

Not specified

Similar Trials